Cargando…

Lower serum brain-derived neurotrophic factor levels are associated with failure to achieve remission in patients with major depression after escitalopram treatment

BACKGROUND: Remission, the primary goal of treatment for major depressive disorder (MDD), is the absence of significant signs or symptoms and the return to a state of normal functioning. A recent study found that the level of brain-derived neurotrophic factor (BDNF) increased after antidepressant tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Bun-Hee, Park, Young-Min, Um, Tae Hyun, Kim, Sollip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114913/ https://www.ncbi.nlm.nih.gov/pubmed/25092985 http://dx.doi.org/10.2147/NDT.S64913

Ejemplares similares

Serum BDNF Levels in Relation to Illness Severity, Suicide Attempts, and Central Serotonin Activity in Patients with Major Depressive Disorder: A Pilot Study
por: Park, Young-Min, et al.
Publicado: (2014)

ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression
por: Singh, A B, et al.
Publicado: (2012)

Sexual functioning in females with depression in remission receiving escitalopram
por: Roy, Pritha, et al.
Publicado: (2019)

Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study
por: Saragoussi, Delphine, et al.
Publicado: (2017)

Reproducibility of the Efficacy of Escitalopram in Patients with Major Depression Who Had Previously Remitted with Escitalopram
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Ali, Mazen K, et al.
Publicado: (2011)

PS179. A depressive patient who achieved remission by escitalopram: cerebral blood flow variation during pleasant/unpleasant image tasks.
por: Shoji, Yoshihisa, et al.
Publicado: (2016)

Effect of Escitalopram on White Blood Cells in Patients With Major Depression
por: Canan, Fatih, et al.
Publicado: (2009)

Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy
por: Mencacci, Claudio, et al.
Publicado: (2013)

3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders
por: Avram, Speranta, et al.
Publicado: (2010)

Towards achieving remission in the treatment of depression
por: Mendlewicz, Julien
Publicado: (2008)

Serum brain-derived neurotrophic factor levels and personality traits in patients with major depression
por: Nomoto, Hiroshi, et al.
Publicado: (2015)

Proteomic Analysis of Serum from Patients with Major Depressive Disorder to Compare Their Depressive and Remission Statuses
por: Lee, Jiyeong, et al.
Publicado: (2015)

Comparing the Effects of Bupropion and Escitalopram on Excessive Internet Game Play in Patients with Major Depressive Disorder
por: Nam, Beomwoo, et al.
Publicado: (2017)

Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression
por: Leonard, Brian, et al.
Publicado: (2010)

Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study
por: Jeong, Jong-Hyun, et al.
Publicado: (2015)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi, Taro, et al.
Publicado: (2017)

CYP2C19 polymorphisms and outcomes of Escitalopram treatment in Brazilians with major depression
por: Bernini de Brito, Rodrigo, et al.
Publicado: (2020)

An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2022)

Evaluation of Serum Glial Cell Line-derived Neurotrophic Factor in Bangladeshi Major Depressive Disorder Patients
por: Das, Rajesh, et al.
Publicado: (2019)

Brain-derived neurotrophic factor promoter methylation and cortical thickness in recurrent major depressive disorder
por: Na, Kyoung-Sae, et al.
Publicado: (2016)

quality of remission in the major depressive disorder
por: Chebli, H., et al.
Publicado: (2023)

Depression in Acromegaly Treated with Escitalopram and Cognitive Therapy
por: De Sousa, Avinash
Publicado: (2009)

Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression
por: Shao, Shichuan, et al.
Publicado: (2022)

Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability
por: Kirino, Eiji
Publicado: (2012)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton, Benchalak, et al.
Publicado: (2018)

Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression
por: MahmoudianDehkordi, Siamak, et al.
Publicado: (2021)

Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder
por: Alkahtani, Manal E., et al.
Publicado: (2021)

Escitalopram-induced akathisia in a patient with major depressive disorder: A rare case report
por: Arshad, Hareem, et al.
Publicado: (2022)

Tissue-Specific Oxysterols as Predictors of Antidepressant (Escitalopram) Treatment Response in Patients With Major Depressive Disorder
por: Sun, Zuoli, et al.
Publicado: (2023)

PS85. Efficacy and Safety of Generic Escitalopram (Lexacure) in Patients with Major Depressive Disorder: A 6-week, Multi-center, Randomized, Rater-blinded, Escitalopram-comparative, Non-inferiority Study
por: Jeong, Jong-Hyun, et al.
Publicado: (2016)

Serum Prolactin and Macroprolactin Levels among Outpatients with Major Depressive Disorder Following the Administration of Selective Serotonin-Reuptake Inhibitors: A Cross-Sectional Pilot Study
por: Kim, Sollip, et al.
Publicado: (2013)

Low Escitalopram Concentrations in Patients with Depression predict Treatment Failure: A Naturalistic Retrospective Study
por: Hart, Xenia M., et al.
Publicado: (2023)

CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression
por: Han, Kyu-Man, et al.
Publicado: (2013)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang, Jia, et al.
Publicado: (2018)

Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder
por: Martens, Marieke A. G., et al.
Publicado: (2021)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis
por: Yin, Juntao, et al.
Publicado: (2023)

Serum Brain-Derived Neurotrophic Factor, and Plasma Catecholamine Metabolites in People with Major Depression: Preliminary Cross-Sectional Study
por: Yoshimura, Reiji, et al.
Publicado: (2018)

Time to achieve remission determines time to be in remission
por: Schipper, Lydia G, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_7s053r7rbs1dmvom9rscq5m6q1